Regeneron will pay Alnylam $800 million to get RNAi into the eye and brain

Regeneron will pay Alnylam $800 million to get RNAi into the eye and brain

The partnership will test the potential of moving RNAi drugs out of the liver and into ocular and central nervous system diseases 

  • 0 Likes

  • 0 Comments